Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences Holdings Corporation (IART) reported Q2 2022 revenues of $398 million, reflecting a 2.0% increase year-over-year. Adjusted earnings per diluted share reached $0.82, up from $0.79 in the previous year. The company has updated its full-year 2022 guidance, expecting revenues between $1,557 million and $1,575 million, amid divestiture plans for its non-core traditional wound care business. Strong performance in the Codman Specialty Surgical and Tissue Technologies segments was noted, along with cash flow from operations of $66 million.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) has appointed Renee Lo as an independent director, effective July 18, 2022. Lo brings significant experience in digital transformation from her role at Microsoft, where she leads data and AI business in Asia. She has a background at Amazon Web Services and extensive experience in the technology sector, holding leadership roles in product development and corporate strategy. This addition aims to enhance the board's capability in delivering shareholder value.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2022 financial results on July 27, 2022, before the market opens. Following the release, management will hold a conference call at 8:30 a.m. ET, accessible by calling 800-289-0720 with the passcode 2688312. A webcast of the call will also be available on their website, with a replay accessible until August 7, 2022. Integra specializes in regenerative tissue technologies and offers a broad portfolio of recognized brands aimed at enhancing patient care.
On May 11, 2022, Hilco Redevelopment Partners announced that Integra LifeSciences (IART) will occupy 100,000 square feet of newly redeveloped space at 400 Wood Road in Braintree, MA. This facility will manufacture surgical reconstruction devices, contributing significantly to local job creation with at least 150 new positions. The Braintree Town Council approved a tax increment financing (TIF) agreement to support this development. Integra plans to achieve full occupancy by late 2025, aiming to positively impact the local economy.
Integra LifeSciences Holdings Corporation (IART) reported Q1 2022 revenues of $376.6 million, a 4.6% increase year-over-year. GAAP earnings per diluted share declined to $0.39 from $0.53 in Q1 2021, while adjusted EPS rose to $0.74 from $0.69. The company raised its 2022 organic growth guidance from 3.5%-5% to 3.8%-5.2% and reaffirmed total revenue growth at 2.5%-3.5%. The gross margin improved to 62.1%. Cash flow from operations was $44 million, with net debt of $1.15 billion.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its first quarter 2022 financial results on April 27, 2022, before the market opens. The management team will host a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing (800)-289-0720 or via a live webcast on the company’s website. A replay will be available until May 7, 2022. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a diverse range of high-quality brands.
Integra LifeSciences (Nasdaq: IART) has launched the NeuraGen® 3D Nerve Guide Matrix, a resorbable implant designed to repair peripheral nerve discontinuities. This innovative product combines bovine type 1 collagen with a unique inner matrix featuring porous channels, promoting Schwann cell migration and axonal growth for enhanced recovery after mid-gap nerve repairs. With approximately 50,000 nerve repair procedures performed annually, NeuraGen 3D aims to improve patient outcomes. The launch represents a significant advancement in Integra's peripheral nerve repair portfolio.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its Q4 2021 and full-year results on February 23, 2022. Q4 revenues reached $405.5 million, up 4.3% year-over-year, with GAAP EPS at $0.53, down from $1.09 in Q4 2020. For the full year, revenues were $1,542.4 million, a 12.4% increase, with GAAP EPS rising to $1.98 from $1.57. The company provided 2022 guidance, projecting revenue growth of 2.5% to 3.5% and adjusted EPS between $3.27 and $3.35.
Integra LifeSciences (IART) announced preliminary revenue results for Q4 and full-year 2021, with Q4 revenue expected between $404 million and $406 million, marking a 4% increase year-over-year. Full-year revenue is projected at $1,541 million to $1,543 million, reflecting a 12% increase. The company plans a $125 million share repurchase under an existing $225 million authorization. CEO Jan De Witte expressed optimism about the company's growth strategies, including product launches and international expansion, reaffirming long-term organic growth targets of 5%-7%.
BD (Becton, Dickinson and Company) announced the formation of a nine-person board of directors for Embecta Corp., which will hold BD's Diabetes Care business after the planned spinoff. The board will be led by David F. Melcher and include notable members such as Claire Pomeroy and Christopher R. Reidy. Devdatt Kurdikar will serve as CEO of Embecta. The spinoff is expected to be completed in Q2 2022, pending regulatory approvals. The governance structure includes various committees, and directors will serve staggered terms.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
